Table 2 Patients characteristics and individual results of allo-SCT

From: Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment

Patient #	Age at allo-SCT	RMS type	Alveolar translocation	Stage at diagnosis	First-line surgery	First-line irradiation	First-line response	Prior auto-SCT before allo-SCT	Year of last allo-SCT	Time to recurrence	Reason for allo-SCT	Conditioning regimen for allo-SCT	Remission status at allo-SCT	Myeloablative intention	Graft source	HLA donor	Acute GvHD	Chronic GvHD	Post allo-SCT DLI	PFS after allo-SCT (months)	Overall survival after allo-SCT (months)	Status at last follow-up
1	22	Alveolar	UK	IV	Yes	No	CR	No	2002	⩾1.5 years	Relapse after initial treatment	FLU/TREO	Residual disease	Yes	PB	Identical sibling	None	Extensive	No	10	12	DOD
2	15	UK	UK	II	No	No	PR	No	2002	n.a.	No CR	CTX/BU/ETO	CR	Yes	BM	Identical related	Yes, grade UK	Limited	No	12	12	DOC (infection)
3	17	UK	UK	IV	No	Yes	CR	No	2001	<1.5 years	Relapse after initial treatment	CTX/BU/ETO	CR	Yes	PB	Identical related	None	None	No	119	119	Alive in CR
4	19	UK	UK	IV	No	Yes	CR	No	1997	<1.5 years	Relapse after initial treatment	CRBPL/MEL/TT	CR	Yes	PB	Identical sibling	None	None	Yes (2x)	6	8	DOD
5	13	Alveolar	UK	IV	No	Yes	PR	No	2007	n.a.	No CR	CRBPL/TOPO/TT	CR	Yes	BM	Identical sibling	None	Limited	No	12	15	Relapse and DOC (infection)
6	25	Alveolar	UK	IV	No	Yes	PR	No	2004	n.a.	No CR	FLU/BU/TT	CR	Yes	PB	Matched unrelated	None	n.a.	No	2	2	DOC (veno-occlusive disease)
7	28	Alveolar	Positive	IV	No	No	PR	No	2005	n.a.	No CR	FLU/MEL/TT	CR	Yes	PB	Mismatched relative	Grade III	Extensive	No	5	7	DOD
8	17	Alveolar	UK	IV	Yes	Yes	PR	No	2005	n.a.	No CR	CTX/BU	Residual disease	Yes	BM	Identical sibling	None	None	No	3	27	DOD
9	14	Embryonal	Negative	IV	Yes	No	PR	No	2003	n.a.	No CR	CTX/BU/TT	CR	Yes	BM	Identical sibling	None	None	Yes (7x)	28	97	Alive in CR
10	17	Alveolar	UK	UK	Yes	Yes	CR	No	2011	<1.5 years	Relapse after initial treatment	FLU/MEL/TREO	CR	Yes	BM	Identical sibling	None	n.a.	No	2	2	Alive in CR
11	6	Alveolar	UK	III	No	Yes	CR	No	2009 (graft failure)	<1.5 years	Relapse after initial treatment	FLU/CTX + TBI 2Gy	CR	No	CB	Mismatched Unrelated	None	n.a.	No	4	5	DOD
12	17	UK	UK	III	UK	UK	UK	Yes	2000	<1.5 years	Relapse after initial treatment	TT	Residual disease	No	BM	Identical sibling	Grade III	None	No	4	4	DOD
13	18	Alveolar	Positive	IV	No	No	CR	Yes	2010	<1.5 years	Relapse after initial treatment	FLU/BU	CR	No	PB	Unrelated 10/12 match	Grade I	None	No	2	4	DOD
14	4	Alveolar	UK	UK	No	No	PR	No	2009	n.a.	No CR	FLU/CTX + TBI 2Gy	Residual disease	No	CB	Unrelated 6/8 match	None	None	No	1	2	DOD
15	17	Alveolar	Positive	IV	Yes	No	CR	Yes	2010	n.a.	Stage IV at Diagnosis	FLU/BU	CR	No	BM	Identical sibling	None	None	No	9	9	Alive in CR
16	13	Alveolar	Positive	IV	No	Yes	PR	No	2009	n.a.	Stage IV at Diagnosis	MEL/TT	CR	No	BM	Identical sibling	None	None	No	3	8	DOD
17	7	Embryonal	Negative	IV	No	Yes	PR	No	2006	<1.5 years	Relapse after initial treatment	CTX/TT	Residual disease	No	BM	Identical sibling	None	None	No	2	8	DOD
18	16	Alveolar	UK	UK	Yes	Yes	PR	No	2007	n.a.	No CR	CTX/TT	CR	No	BM	Matched unrelated 8/8 match	Grade I	None	No	3	19	DOD
19	26	Alveolar	Positive	IV	No	No	PR	Yes	2002	n.a.	No CR	FLU/CTX	CR	No	PB	Identical sibling	Grade III	Limited	Yes (1x)	10	13	DOD
20	13	Alveolar	Positive	IV	Yes	Yes	PR	No	2009 (graft failure)	n.a.	No CR	FLU/CTX + TBI 2Gy	CR	No	CB	Mismatched unrelated	None	n.a.	No	1	2	DOD
21	16	Alveolar	Positive	IV	Yes	Yes	CR	No	2008	⩾1.5 years	Relapse after initial treatment	FLU/BU	CR	No	BM	Unrelated 12/12 match	Grade I	None	No	28	28	Alive in CR
22	10	Alveolar	Negative	IV	Yes	Yes	CR	No	2009	<1.5 years	Relapse after initial treatment	FLU/BU	Residual disease	No	BM	Identical sibling	None	n.a.	No	3	3	DOD
23	16	Alveolar	Negative	IV	Yes	No	CR	No	2006	n.a.	Stage IV at Diagnosis	FLU/MEL	CR	No	BM	Matched unrelated 10/10 match	Grade II	None	No	60	60	Alive in CR
24	5	Embryonal	Negative	III	Yes	UK	PR	No	2006	n.a.	No CR	FLU/MEL	CR	No	PB	Mismatched relative	None	None	No	62	62	Alive in CR
25	17	Alveolar	UK	IV	No	Yes	PR	Yes	2003	n.a.	No CR	MEL/TT	CR	No	BM	Identical sibling	None	None	No	7	17	DOD
26	6	Alveolar	UK	IV	Yes	No	PR	Yes	2009	n.a.	No CR	MEL/TT	CR	No	BM	Identical sibling	Grade III	None	No	7	12	DOD
27	10	Alveolar	Positive	IV	No	Yes	PR	Yes	2008	⩾1.5 years	Relapse after initial treatment	MEL/TT	CR	No	PB	Matched unrelated	Grade IV	n.a.	No	1	1	DOC (GvHD)
28	11	Alveolar	UK	IV	Yes	Yes	PR	Yes	2010	n.a.	No CR	MEL/TT	CR	No	BM	Matched unrelated	Grade II	None	No	8	8	Alive in CR
29	14	Alveolar	Positive	IV	Yes	Yes	PR	No	2007	n.a.	No CR	FLU/BU	CR	No	PB	Identical sibling	Grade III	None	No	1	7	DOD
30	10	Alveolar	UK	IV	Yes	Yes	PR	Yes	2008	⩾1.5 years	Relapse after initial treatment	FLU/CTX+TBI 2 Gy	CR	No	CB	Mismatched unrelated	Grade II	None	No	3	19	DOD

Abbreviations: allo-SCT=allogeneic stem cell transplantation; auto-SCT=autologous stem cell transplantation; BU=busulfan; CR=complete response; CRBPL=carboplatin; CTX=cyclophosphamide; DOC=death of complications; DOD=death of disease; ETO=etoposide; GvHD=graft-vs-host disease; PR=partial response; PFS=progression-free survival; n.a.=not assessable; RMS=rhabdomyosarcoma; MEL=melphalan; TBI,=total body irradiation; TOPO=topotecan; TREO=treosulfan; TT=thiotepa; UK=unknown.

Back to article page

Table 2 Patients characteristics and individual results of allo-SCT

Search

Quick links